+、CD8+、CD4+/CD8+、C3、C4水平均無統(tǒng)計學(xué)差異;治療后,對照組CD4+、CD8+、CD4+/CD8+水平與治療前比較差異不顯著;觀察組患者的CD4+、CD4+/CD8+水平均顯著升高,CD8+水平顯著降低(P<0.05);治療后,兩組C3、C4水平均顯著高于治療前(P<0.05);且觀察組患者的C3、C4水平均顯著高于對照組(P<0.05)。觀察組不良反應(yīng)總發(fā)生率為23.91%,與對照組不良反應(yīng)總發(fā)生率24.49%比較,差異無統(tǒng)計學(xué)差異。結(jié)論 重組人干擾素α-2b聯(lián)合恩替卡韋治療慢性乙型肝炎的效果顯著,該方法可有效改善患者的免疫功能、且不良反應(yīng)未增加,臨床應(yīng)用價值較高。;Objective To analyze the effect of pegylated interferon alfa-2b plus entecavir on immune function in patients with chronic hepatitis B.Methods We selected 95 patients with chronic hepatitis B treated in our hospital between January 2016 and January 2018 as subjects. According to the order of admission, they were randomly divided into a control group of 49 patients (treated with entecavir) and a study group of 46 patients (treated with pegylated interferon alfa-2b plus entecavir). The treatment effect of the two groups of patients was compared.Results The total effective rate of treatment in the study group was (89.13%) significantly higher than that of the control group (77.55%) (P<0.05). Before treatment, there was no significant difference in the levels of CD4+, CD8+, CD4+/CD8+, C3, and C4 between the two groups. After treatment, the levels of CD4+, CD8+, and CD4+/CD8+ in the study group were significantly lower than those in the treatment group (P<0.05); C3 and C4 levels in study group were significantly lower than before treatment and control group (P<0.05). The incidence of adverse reactions in the study group was 23.91%, and 24.49% in the control group was not statistically different.Conclusions The effect of pegylated interferon alfa-2b combined with entecavir in the treatment of chronic hepatitis B is significant. This method can effectively improve the patient's immune function and does not increase the adverse reactions. The clinical application value is high."/>